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Background and Objective: 
Real-world data (RWD) is characterized as data derived from multiple sources associated with 
the process in real-world practice in a heterogeneous patient population. There is a growing 
interest in using Real-World Data and Real-World Evidence in biomedical research since RWE 
presents an opportunity to extend the research beyond the typical limits of academia. However, 
the traditional statistics methods used in RWD analysis may lead to bias and challenge the 
credibility of RWE. To document what analytics methods have been used in RWD analysis, we 
conducted a sampled methodological review of methods used in EHRs based biomedical 
research. 
Methods:  
We developed an article database to document literature characteristics and analytical methods. 
We took a random sample of articles for detailed review. The primary outcome was proportion 
of articles using RWD methods. Meta-regressions were utilized to examine trends in proportion 
changes over time. 
Results:  
Of 88 papers reviewed in detail, 7 (8.0%) used the recommended Real-World Method (RWM). 
The proportion (and 95% confidence interval) of publications reporting having used RWM, 
performed sensitivity analysis, and handled missing data problem in 2019 were 11% (0, 26%), 
17% (0, 34%) , and 22% (3%, 41%), respectively. Results of the sensitivity analysis showed the 
proportion of use RWM increased 0.4% per year, although this slope was statistically equivalent 
to 0.  
 iii 
Conclusions: The proportion of the EHRs based studies handling missing data, using RWM, or 
performing sensitivity analysis is disappointingly low. Although regulator guidelines, books, and 
academic meetings have suggested during the study period methods should be used in RWD 
analysis, the proper analytic methods are inadequately used in the published studies. 
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Real-World Data and Real-World Evidence in biomedical research  
Using Real-World Data (RWD) to generate Real-World Evidence (RWE) is playing an 
increasing role in health care decisions worldwide [1] . There is a growing interest in using RWD 
in biomedical research by stakeholders, including policymakers, biomedical researchers, 
clinicians, and medical product developers. [2-8] Investigators believe that data objectively 
collected from a broad spectrum of therapeutic areas in routine care reflects the real-world 
practice. RWE that generated with RWD has the potential to support the regulatory decision-
making, therapies discovery and evaluation, and clinical practice. The expected benefits of 
collecting data and extracting it from routine care settings are not only to improve study 
generalizability and reduce costs, but also to extend the available evidence for patients with 
substantial heterogeneity, multi-morbidity, and more severe forms of disease than would 
typically be allowed in a Random Controlled Trial (RCT) which is still the gold-standard of 
clinical research[9]. Using real-world data and real-world evidence in biomedical research will 
improve research feasibility and close the gap between clinical science and practice.[8] 
Why now 
In the United States, the U.S. Food & Drug Administration (FDA) has long been interested in 
using data generated in the real world to learn about medical products, including drugs, vaccines, 
biologics, and medical devices. In May 2008, the FDA launched the Sentinel Initiative, which is 
the national electronic system for researchers to monitor the safety of FDA-regulated medical 
products to protect public health [10].  Data from real-world practice were broadly collected after 
the Health Information Technology for Economic and Clinical Health Act (HITECH Act) was 
 2 
signed in law in February 2009. [11]. Furthermore, The 21st Century Cures Act (Cures Act) in 
the U.S. was signed into law in 2016. The Congress requires “Not later than 2 years after the 
date of enactment of the 21st Century Cures Act, the Secretary shall establish a program to 
evaluate the potential use of real-world evidence.” [12] The Act was designed to accelerate the 
development of medical products and to bring innovations and advancements to stakeholders 
who need them more efficiently and effectively[12 13]. It would also bring Congressional 
pressure on FDA inspectors to rely on RWD and RWE. FDA has developed guidelines on the 
various uses of RWE, for example, Best Practices for Conducting and Reporting 
Pharmacoepidemiological Safety Studies Using Electronic Health Records[14], Use of 
Electronic Health Record Data in Clinical Investigations-Guidance for Industry[15]. FDA’s 
guidelines approved different research designs that can generate RWE, including but not limited 
to randomized trials, including big, simple trials, pragmatic trials, and observational studies. The 
guidelines of data analysis and RWE generation methodology are still under discussion. [1 14-
17]  
Why is it important 
Although Real-World Data can be used in broad topics in biomedical research for multiple 
purposes, without a valid methodologic approach, including controlling source-data quality, 
choosing a proper study design, using correct analytical methods, sensitivity analysis of the 
results, RWD can lead to biased conclusions that cannot be used as the evidence to guide health 
care decision-making [17-19].  
In the “Big Data Era”, investigators are zealous about applying Artificial Intelligence, Machine 
Learning methods in the healthcare industry. Although the healthcare field has “big” volume and 
“big” variety data, the high-quality data that could be used to extract information and generate 
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clinical evidence using Artificial Intelligent (AI) or Machine Learning (ML) methods are limited. 
Using an improper or limited method to create Real-World Evidence from Real-World Data and 
then applying that RWE in real-world practice, may result in false treatment of patients, in waste 
of R&D funds, and in a delay of the study, each of which is the opposite of the expectation of 
using RWD in the research. Biomedical research results that were developed through machine 
learning methods, even with high accuracy, are not explainable and lack of robust causal 
reasoning[20]. Considering the cost and benefit of bringing new drugs and therapies into the 
biomedical research and development process, appropriate analytic methods designed for RWD 
and RWE should be used in the research. 
Rationale for review 
Several reviews have been done for the definition, opportunities, and challenges of using RWD 
and RWE, regulators and research institutions provided recommendations for how to generate 
RWE from RWD. EHRs are being used for research purposes, but because they comprise RWD, 
EHRs based research should use methods that suggested in books and guidelines that fit for 
RWD analysis.  A research gap in systematically assess the published RWE quality exists. In 
conclusion, there is a need to review what analytic methods are used in biomedical research 
based on EMR data. In this paper, we review and document what data analysis methods are used 




Real-World Data to Real-World Evidence  
Real-world data (RWD) is characterized as data derived from multiple sources associated with 
process in real-world practice in a heterogeneous patient population. U.S. FDA defines Real-
world data as “the data relating to patient health status and the delivery of health care routinely 
collected from a variety of sources.” Example data sources include: 1) Electronic Health Records 
(EHRs) ; 2) Claims and billing records; 3) Product and device registries; 4) Patient-generated 
data including in home-use settings; 5) Data gathered from other sources that can inform on 
health status, such as mobile devices [1].  
Real-World Evidence is a concept widely discussed in the Evidence-Based Medicine (EBM), but 
there is no one universally accepted definition for the RWE. U.S FDA defines RWE as “the 
clinical evidence regarding the usage, and potential benefits or risks, of a medical product 
derived from analysis of real-world data” [1]. The U.S. Congress defined the RWE as “Any data 
on the application, or potential benefits or risks, of a product obtained from sources other than 
randomized clinical trials.” The Cures Act recognized the potential use of real-world evidence to 
help to support the approval of new indication for a drug, and to help to support a satisfied post-
approval study requirement [12]. European Medicine Agency  (EMA) “Real-World Evidence 
meaning evidence coming from registries, electronic health records, and insurance data, etc. 
where studies may be required by regulators through scientific advice, CHMP or PRAC and the 
subsequent results are used to inform regulatory and potentially HTA decision-making ” [21]  
Real-World Evidence is always compared with the gold-standard evidence from biomedical 
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research of Randomized Control Trial (RCT). Although RCT is the gold standard for 
establishing causal relationships analysis under ideal conditions, which includes a rigorous 
patient selection process and well-defined inclusion exclusion criteria, an RCT is  not always 
practical. For instance, RCTs do not always represent the heterogeneous clinical population of 
patients, in practice. RWE offers insights into patient experiences in real-life environments, as 
opposed to the carefully planned conditions of experimental settings in healthcare. Also, RWD 
can be used to generate evidence complementing existing knowledge for the use of medical 
products in patients who are under-represented or excluded from the trial populations. 
Investigators expect RWE can provide information and expertise to researchers to answer 
questions in healthcare outcomes research, patient care, safety surveillance, and therapeutic 
development more effectively[9]. Based on the analysis of the ‘real-world’ medical history of 
patients dating back several years, data gathered from a larger patient population and evidence of 
real-practice patient compliance. RWE complements traditional RCT data and, as such, paints a 
broader picture of approaches used in the prevention, diagnosis, and management of particular 
diseases and long-term health. The application of RWD is not limited to RWE generation. Real-
world data can be used to aid in the design of a clinical trial by: 1)  assisting in the selection of 
research sites that are most likely to recruit test participants[22 23] ,  2) providing a basis for 
power calculation[22 24] 3). creating a prior for a Bayesian statistical analysis, 4). and providing 
an alternative control group and guidance enrichment. (Jarow, LaVange et al. 2017, Sturmer, 
Wang et al. 2020).  RWD  can also be used during a trial to minimize duplication of data input, 
such as the medical history of the subject, automatic recording of adverse effects, and endpoints. 
[22] 
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A study listed 22 drugs, in which the FDA and EMA used RWE to support regulatory efficacy 
decisions leading to accelerated approval, full authorization or expansion of labels in the last 10 
years [3]. While the expectation of using RWD and RWE is increasing, going from Real-world 
Data to Real-World Evidence is hard. Research in 2017 showed that the exist RWD can replicate 
only 15% RCTs in 2017 because of the data quality and study design limitation. [2 25] The 
results generated from RWD limited by unmeasured biases and confounding [20] [3] Therefore, 
Development of novel methodologies to produce RWE that provides adequate scientific 
evidence is needed. 
Guidelines for Using RWE and RWD 
Many guidelines and Act were published in last 10 years may facilitate the research on RWD 
based biomedical study. For instance, Best Practices for Conducting and Reporting 
Pharmacoepidemiological Safety Studies Using Electronic Health Records was published in 
[14], 21st Century Cures Act [12] and Guidelines for good pharmacoepidemiology practice 
(GPP) were published in 2016 [26].   
Table 1 Guidelines for Using RWE and RWD 
Name Published time  Agency 
Framework for FDA’s Real-World Evidence Program[17] 2018 FDA 
21st Century Cures Act[12] 2016 The Congress 
Submitting Documents 
Using Real-World Data 
and Real-World Evidence 
to FDA for Drugs and 
Biologics-Guidance for Industry[16] 
2019 FDA 
Guidelines for good pharmacoepidemiology practice 
(GPP)[26] 
2016 
International Society of 
Pharmacoepidemiology 
Use of Electronic Health Record Data in Clinical 
Investigations-Guidance for Industry[15] 
 
July 2018 FDA 
Best Practices for Conducting and Reporting 
Pharmacoepidemiological Safety Studies Using Electronic 
Health Records[14] 
May 2013 FDA 
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Electronic Health Records as the Data source 
Electronic Health Records (EHRs) are a major source of data that could generate RWD [17]. The 
scope of Electronic Health Records may be different in different health systems. We define the 
EHRs using the U.S. FDA definition in the guideline Use of Electronic Health Record Data in 
Clinical Investigations: “an EHR is an individual patient record contained within the EHR 
system. A typical individual EHR may include a patient’s medical history, diagnoses, treatment 
plans, immunization dates, allergies, radiology images, pharmacy records, and laboratory and 
test results” in this study  [15].  The EHR is designed to optimize diagnosis or clinical care, as 
well as used to enhance the relevance of biomedical research. [17 19] Data obtained from EHRs 
always include structured information as the demographics, laboratory results(LONIC), 
procedures record (CTP code), clinical characteristics (ICD, LONIC),  medications(patients 
outcomes, and unstructured information, for example, physician notes (notes from COPD 
system). It can also include unstructured data that, through text processing or natural language 
processing (NLP), can be turned into structured data as well.[27] 
The HITECH Act encouraged health care providers to adopt Electronic Health Records Systems 
and improve health care data privacy and safety protection [11]. By the mid 2010s, over 86% of 
hospitals had their data stored in such records.[28] There is, therfore, a vast amount of healthcare 
data potentially available for study But how best to use such data is still under debate. The FDA 
is aware of recent attempts to use robust design and statistical methods to reproduce randomized 
study outcomes with observational studies and to derive general rules that could improve the 
likelihood of achieving reliable results using RWD in the design of observational studies[17].  
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Analytic Methods should be used for EHR data  
EHRs comprise intrinsically longitudinal data that are collected in the routine delivery of patient 
care.[19] Challenges of using EHRs in biomedical research are recognized by many researchers.  
They can be categorized as IT systems challenges, data challenges, analytics methods challenges, 
and clinical knowledge challenges[19 25 29 30]. 
 
 
As is stated in Guidelines for Good Pharmacoepidemiology Practices (GPP): 
“Data analysis comprises comparisons and methods for analyzing and presenting 
results, categorizations, and procedures to control sources of bias and their influence on 
outcomes, e.g., the possible impact of biases due to selection bias, misclassification, 
confounding, and missing data.[26]” 
Furthermore, that the analysis method should 
“be directed toward the unbiased estimation of the epidemiologic parameters of interest. 
The precision of effect estimates should be quantified using confidence intervals. 
 
Table 2 Challenges of Using EHRs 
Category Problem 
System challenge 
Lack of standardization, e.g. data transfer protocols  
Interoperability within health information systems 
 
Data challenge 
Missing data / field  
Data quality validation 
Data gathering and integration 




Study design based on research topic  
Study design to address missing data/ data problem 
Need for computable phenotype 
 
Clinical knowledge 
Are the results applicable for the clinical setting  
Cohort definition validation  
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Comparability of populations for pooled estimates should be assured, and missing 
important variables should be addressed. Interpretation of statistical measures, including 
confidence intervals, should be tempered with appropriate judgment and 
acknowledgements of potential sources of error and limitations of the analysis and 
should never be taken as the sole or rigid basis for concluding that there is or is not a 
relationship between an exposure and outcome. Sensitivity analyses should be conducted 
to examine the effect of varying potentially critical assumptions of the analysis”.  
“’Any sensitivity analyses should be described.’[26]” 
From the guideline - Best Practices for Conducting and Reporting Pharmacoepidemiologic 
Safety Studies Using Electronic Healthcare Data- at a minimum, a research program should 
provide information on statistical models and tests, estimation of sample size, study meaning 
level ad strength, handling of missing values, analysis of subgroups and assessment of effect 
change, and confounding adjustment process [14].  
As the Framework for FDA’S Real-World Evidence Program stated:  
In considering whether data gathered through observational study designs are 
appropriate to generate RWE for the purpose of supporting effectiveness determinations, 
FDA intends to evaluate multiple questions of interest that could affect the ability to draw 
a reliable causal inference.[17] 
Methods that could draw causal inference should be used in the RWD analysis.[17].  
Rationale for using a sampled scoping review  
Previous reviews and guidelines sought to understand the RWD and RWE at a theoretical level 
to assess the potential challenges and opportunities of using RWE. Real-world data analytic 
methods were discussed in industry guidelines, books, and academic meetings in past years. 
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However, it is unknown whether the analytic methods used in RWD analysis were applied as 
recommended. For these reasons, we conducted a scoping review to document analytic methods 
used in published RWD studies in the last 10 years, to identify any gaps in the RWD research. 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
Extension for Scoping Review(PRISMA-ScR) checklist- an evidence-based minimum set of 
items for reporting scoping reviews- in this scoping review.  [31] 
Objectives and focus of review 
To document what analytic methods investigators used from RWD to generate RWE. Focus on  
biomedical research papers that used Electronic Health Records as the main data source. 
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Methods 
To document the current status of Real-World Evidence analytical methods in studies based on 
EMR data, we conducted a sampled methodological review to analyze the analytical methods 
used in the EHR-based biomedical research. From regulator guidelines, books, and RWD 
meeting recommendations we identified a list of analytic methodologies that should be used in 
Real-World Data analysis and coded them as “RWE methods”. [14-20 26 32] In past 10 years, 
thousands of papers related to Real-world Evidence were published. To review the overall 
quality of the RWE papers, we used statistical inference to estimate the proportion of the papers 
used RWE methods out of all the papers. Two reviewers (CL and RA) checked the methods 
independently.  
Scoping of the literature  
This review aimed for summarizing analytic methods used in biomedical research that used 
EHRs as main data source from 2010-2019. We were looking for original quantitative research 
articles that analyzed data collected from real-world practice to answer biomedical questions 
written in English.  The main concepts are “Electronic Health Records”, “Biomedical 
Research”,” Original Study”, and time frame “2010-2019”. 
Search Strategy 
We searched peer-reviewed articles in PubMed (MEDLINE) the major biomedical literatures 
database. The search term “Electronic Health Records” was extracted from MEDLINE / PubMed 
Search Strategy & Electronic Health Record Information Resources the version reviewed on 
May 24, 2019. [33], “Biomedical Research” was extracted from PubMed publication type “Study 
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Characteristics” which used as a broad strategy for research that use empirical methods include 
most of quantitative and qualitative biomedical research. Clinical Study[Publication Type] and 
Observational Study[publication type] is a subset of the Study Characteristics[Publication Type]. 
We exclude review articles by using “NOT Review[Publication Type] AND Systematic 
Review[Publication Type].[34]  To limit the result to quantitative biomedical studies have data 
analytic methods, we added keywords "data"[All Fields] AND "analy*"[All Fields] to the search. 
We used PubMed clinical filters to focus on diagnosis, etiology, prognosis studies, the broad 
definition for searching diagnosis, etiology, and prognosis has sensitivity of 90% ,  93% , and 
90% , respectively.[35] Since the Electronic Health Systems were  we limit the publication date 
to 2010/01/01-2019/12/31 using PubMed filters “2010/01/01” [PDat] : “2019/12/31” [PDat]. The 
detailed search strategy sees Appendix 1. 
Developing of the Environment 
EndNote 
The articles extracted from PubMed Search were saved as a .nbib file (Appendix 2)mported to 
EndNote X9 library for further reading and annotation. Research objectives, study design, data 
source, analytic tools, analytic methods, and other relevant literature were highlighted in each 
article we read for this review. The notes were saved in the EndNote library for future evaluation 
and reproduce the reading process. (Appendix 3) 
Microsoft Excel Articles Database 
To manage the literature, to record the methods related to each literature, and to synthesize the 
evidence from the literature, we designed a relational database (Appendix 4) for the RWD 
articles we identified from the PubMed search. The Entity-Relationship Diagram is shown 
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Figure 1; detailed definitions were are available in the appendix (Table 9). The tables, 
Article_Review and Methods_Used_in_Literatures, were updated while Reviewer A (CL) 
reading. The database was designed, created and maintained by CL. 
 
Figure 1 ER Diagram for managing the scoping review 
Eligibility 
This paper intends to include studies with original, quantitative, biomedical research used EHRs 
as the primary data source, written in English. The list of inclusion and exclusion criteria was 
developed based on two principles: (1) ensuring that the analysis in the paper was indeed of 
EHR-based data and (2) being wary of excluding studies likely to use RWE methods. 
Inclusion criteria 
We created four inclusion criteria (see Table 3 Inclusion Criteria No.1-4) to sensitively detect the 
articles we need. Based on this, we created a search strategy. 
In the full-text reading process, we specified the inclusion criteria list, supplemented criteria 
No.3a,3b,3c, and No.5-7. 
 14 
Table 3 Inclusion Criteria 
 
Exclusion criteria 
We grew the exclusion list in the course of the study. The primary RWD source in this review is 
routinely collected Electronic Health Record. Therefore we excluded the research that use 
Claims data, Genomic Data, Manually collected Registry Data, RCT data. Articles that focused 
on Physician behavior, Information System evaluation, health services evaluation, and new IT in 
healthcare were excluded. Also, the research used unstructured and semi-structured data which 
need Natural Language Processing or Text mining were excluded. Finally, we got 14 exclusion 
criteria and excluded ineligible papers while full-text reading. 
 Ideally, we should say something about having "grown this list in the course of the study, 
always with the guideline of (1) ensuring that the analysis in the paper was indeed of EHR-based 
data and (2) being wary of excluding studies likely to use RWE methods."   
Analysis and Synthesis process  
Thousands of literatures related to RWD and RWE were published, we aim to identify the 
proportion of papers used particular methods of the whol publication set. A random sampled 
literature set with a satisfactory sample size could present the whole literatures. We recorded 
Number Criterium 
1 Original Data 
2 Quantitative Study 
3 Using the EHRs as the main source of data for analysis 
Allow collections of EHR data 
Either variables or outcomes should come from EHR  
Allow other source of data  combined with the EHRs 
4 Published year 2010-2019 
5 Main Article written in English 
6 Focus is on a biomedical question 
7 National Data bank, if derived mostly from EHR 
 15 
details in study type, study design and methods used in the article of a random sample of studies 
extractd from the MEDLINE.(RWE list see Appendix 4 Excel Database) 
The key outcome variable was whether RWE methods were used. We documented the methods 
used in included papers, then matched the Real-World Methods (RWE) list we identified from 
regulator guidelines, books, and RWD meeting recommendations.[14 15 17 18 20 32 36] Any 
machine learning methods combined with causal inference also were considered as RWM. [32] 
The missing data analytics process performed 1.Deletion methods with examining the sensitivity 
of results to the MCAR and MAR assumptions; [20] 2.Single impulation methods;  3. Model 
based methods , were tagged as handled missing data [20 36] 
Every included paper was reviewed by 2 readers (CL and RA), and judgments logged. 
Characteristics of  the study design type, Country/District, mentioned missing data, etc. were 
documented by CL after reading full-text. The second reader RA reviewed a random sample of 
the articles to recheck for errors in data documentdation or  interpretation. Differences of opinion 
were discussed between the 2 readers and, if necessary, with the mentor (HL). Attention was 
paid to separate sensitivity analysis, which method was suggested be used whether RWE or more 
traditional methods are used [17 20 26] and missing data, which again is a concern in either 
framework[15 17 20 26 32]. 
The proportion of papers within each epoch using RWE, sensitivity analysis, or missing-data 
methods (of any sort) were calculated, along with the confidence interval of every such 
proportion (using bin size as the sample size),  and graphed over time. A meta-regression across 
time was performed as well. 
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Results  
Study Selection Flow 
The study selection flow was summarized using PRISMA 2009 flow diagram (Figure 2)[37]  
 
Figure 2 PRISMA Flow Diagram 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 




PRISM A 2009 Flow Diagram  
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Successful loaded in EndNote to do analysis  
(n =1128 ) 
Full-text articles assessed for eligibility 
(n =   300) 
Full-text articles 
excluded based on 
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(n = 212 ) 
Studies included in qualitative synthesis 






Literatures stratified by year and sampled 
from each time frame (n =300) 
Cannot load in citation 
manager  
(n=2) 
Searching strategy  
Keywords: “EHR”+ “data” 
Publication type: ”Clinical 
Study” and ”Study 
Characteristics” 
Time limitation: 10 years  
Stratify the papers  
Time frame:  
2010-2013:  n=350 
2014-2016:  n=341 
2017:            n=157 
2018:            n=189      
2019:            n=90 
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We conducted the literature searching on March 23rd, 2020 used the search strategy for 
MEDLINE described in Appendix 1. The final search results were exported into EndNote. 
Research papers were identified from the PubMed, the published paper number in each year has 
a trend of increase showed in the Figure 3 Extracted Papers by Year. According to the sample 
size calculation, for an α set at 0.05 , confidence interval at 5,  n=1128, a total sample size of 287  
will be needed.  
 
 
Figure 3 Extracted Papers by Year 
 
Of the 1128 papers retrieved from PubMed, we sampled 300 articles, which is higher than the 
sample size needed to document the study details. We set 10 years as 5 unequal length epochs for 
further analysis. Randomly sampled 300 papers based on 5 epochs to build the Article_Review 
table. The sampling process was performed in Jupyter Notebook (Python 3.7 Random Module) 





Table 4 Articles Numbers by Epoch 
 
 
After the full-text reading,  and applying the inclusion/exclusion criteria. Exclude 212 papers 
reviewed by two readers based on the exclusion criteria list that generated from reading process.  
Excluded paper numbers with reasons see  
Table 5.  Finally, we ended with 88 papers in this review for detailed analytic methods 
evaluation.(Figure 4)  
Year 2010-
2013 
2014-2016 2017 2018 2019 
Total papers 350 341 157 189 91 
Proportion of total 
papers  
31.0% 30.2% 13.9% 16.8% 8.1% 
Sampled for full-text 
reading 
100 50 50 50 50 
  Exclusion Reasons Exclude number 
1 Claim data only 8 
2 EMR data only used to identify the cohort 7 
3 Genomic data   2 
4 Methodology papers  11 
5 Not English 6 
6 Patient generated health data only 6 
7 Physician behavior, system evaluation, health services research [I.e., not 
biomedical] 32 
8 Qualitative data only 5 
9 Questionnaire/survey only 28 
10 RCT data (data where a human being has abstracted the data [adds data quality; 
avoid curated data]) 10 
11 Registry (data where a human being has abstracted the data [adds data quality; avoid 
curated data]) 31 
12 Review papers  3 
13 Technology question(Database build, data collection, datatransmission, IT 
infrastruction ) 60 
14 
Text mining / NLP   3 
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Table 5 Exclusion Reasons 
 
 
  Exclusion Reasons Exclude number 
1 Claim data only 8 
2 EMR data only used to identify the cohort 7 
3 Genomic data   2 
4 Methodology papers  11 
5 Not English 6 
6 Patient generated health data only 6 
7 Physician behavior, system evaluation, health services research [I.e., not 
biomedical] 32 
8 Qualitative data only 5 
9 Questionnaire/survey only 28 
10 RCT data (data where a human being has abstracted the data [adds data quality; 
avoid curated data]) 10 
11 Registry (data where a human being has abstracted the data [adds data quality; avoid 
curated data]) 31 
12 Review papers  3 
13 Technology question(Database build, data collection, datatransmission, IT 
infrastruction ) 60 
14 
Text mining / NLP   3 
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Figure 4 Included Papers by Epochs 
Document Characteristics  
The included paper characteristics were generated by Python TableOne package. We analyzed 
four characteristics by Epoch. Of the 88 included research articles, 67(77.9% ) were designed as 
a retrospective cohort study, 6 (7%) were designed as a retrospective cross-sectional study. The 
missing recorded study design is 2 since the study design was not described in the article, and 
reviewers cannot identify the study type based on the scripts. Many articles have missing 
reported items recommended for the research report, only three papers stated their reports 
followed a checklist, and 15 (17.4%) did not report analytic tools used in the research. The 
Country/District was defined as the country in which the main population in the database. Of all 
the included research, 52  (59.3%) were conducted in the United States, 7 (8%) in the United 
Kingdom,  and 6 (6.8%)  in Korea.
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Table 6 Included Paper Characteristics  
   
INCLUDED PAPERS CHARACTERISTICS GROUPED BY EPOCHS 
 
  Missing Overall 2010-2013 2014-2016 2017  2018  2019  
         
N   
 
88 26 12 18 14 18 
STUDY_DESIGN_TYPE, 
 N (%) 
retrospective cohort study 2 67 (77.9) 21 (80.8) 10 (90.9) 12 (70.6) 10 (71.4) 14 (77.8) 
retrospective cross-sectional study   6 (7.0) 3 (11.5)  2 (11.8)  1 (5.6) 
cluster randomized pragmatic clinical 
trials 
 
1 (1.2) 1 (3.8) 
    

























retrospective chart review 
 
1 (1.2) 1 (3.8) 
    
proof of Concept Study  1 (1.2)    1 (7.1)  
COUNTRY/DISTRICT,  
N (%) 
USA 0 52 (59.1) 16 (61.5) 6 (50.0) 11 (61.1) 7 (50.0) 12 (66.7) 




   
1 (7.1) 1 (5.6) 
Brazil  1 (1.1)   1 (5.6)   
Germany  2 (2.3)  1 (8.3)   1 (5.6) 















4 (28.6) 1 (5.6) 
Netherland 
 






1 (1.1) 1 (3.8) 








1 (1.1) 1 (3.8) 
    
Spain 
 













1 (1.1) 1 (3.8) 
    
Taiwan 
 
1 (1.1) 1 (3.8) 
    
Canada  2 (2.3)  1 (8.3)   1 (5.6) 
China  1 (1.1)   1 (5.6)   
MENTIONED_MISSION_DATA, 
N (%) 
No 0 46 (52.3) 17 (65.4) 5 (41.7) 6 (33.3) 10 (71.4) 8 (44.4) 
Yes Data Analytic 
 
9 (10.2) 1 (3.8) 
 
3 (16.7) 2 (14.3) 3 (16.7) 




3 (25.0) 6 (33.3) 2 (14.3) 3 (16.7) 
Yes Limitation 
 
19 (21.6) 8 (30.8) 4 (33.3) 3 (16.7) 
 
4 (22.2) 
CHECK_LIST, N (%) Guidelines for good 
pharmacoepidemiology practices (GPP) 
85 1 (33.3) 













The extent of agreement among data collectors was measure through interrater reliability testing. 
Reader A (CL) included 94 papers at first; after the second round review with reader B (RA), 88 
papers were included. Cohen’s Kappa was used to measure the eligibility process’s inter-rater 
reliability, κ1=0.95, and the agreement between two reviewers was 98%. 
The analytic methods were recorded in the Excel database by CL and reviewed by RA, the κ2 
=0.97, with 99% agreement.   Cohen suggested the Kappa result of 0.81–1.00  should be 





Equation 1 Cohen’s Kappa 
 
Proportion Analysis 
The primary outcome of interest was the proportion of the Real-world Method used in RWD 
analysis. We used the sample (included papers) proportion to estimate the population (all 
published papers that meet the eligibility) proportion. The point estimator follows normal 
distribution, so the margin of error is the product of the Z value for the desired confidence level 
(in this case, we used Z=1.96 for 95% confidence) and the standard error of the point estimate. 
Confidence intervals( Equation 2 Confidence Interval Calculation) were calculated use Python 
(See, Appendix 5 ) 
 































Equation 2 Confidence Interval Calculation 
 
The estimators of proportion were calculated through the equation above. As the results are 
shown in Table 7 , the estimated proportions of papers used Real-World Methods (RWM) in 
2017, 2018, 2019 are 0.03,0.21,0.11, respectively.  The 95% confidence interval of a proportion 
indicates a range within which, 95 out of 100 times, its estimated value will lie. [39]   
 
Table 7 Proportion estimation and Confidence Interval 
 
Estimated Proportion and Confidence Interval of Methods used in EHRs Based Research 
 2010-2013 2014-2016 2017 2018 2019 
Real-World_Method 0.04 (0, 0.11) 0.08(0, 0.24) 0.03(0, 0.1) 0.21(0, 0.43) 0.11(0, 0.26) 
Sensitivity_Analysis 0.19(0.04,0.34) 0.25(0.01, 0.5) 0.28(0.07, 0.48) 0.07(0, 0.21) 0.22(0.03, 0.41) 





Figure 5 Proportion of Methods Used in the RWD Resesarch 
As the proportion estimator is shown,  95% confidence interval shown in the Table 7 and  Figure 
5 the proportion of using proper methods in Real-World Evidence analysis is disappointingly 
low.  
Meta-regressions 
Meta-regression attempts to describe statistical variability in terms of study-level variables, 
thereby summarizing the information as a function rather than a single value. [40] The regression 
coefficient derived from a meta-regression analysis would explain how the outcome variable 
changes as the possible effect modifier with a cluster; in this case, proportion changes per 
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chronological time unit. The statistical significance of the coefficient is a test of if a linear 
relationship exists between the effect of action and the outcome variable.[40 41] 
We conducted a mixed-effects meta-regression using restricted maximum-likelihood (ReML)   
using  PyMARE, a package that does meta-analyses and meta-regressions in Python. [42]  
Three meta-regression were done with time as the independent variable. Since the epoch length 
is unequal, we used the midpoint of each epoch in the analysis. As the result shown in Table 8. 
The proportion of use RWM increases by 0.4% per year; the upper bound is 3.4%, even use the 
small sample size and upper bound; the proportion of RWM used increases slowly. The p-values  
indicate that we cannot reject the null hypothesis : proportion of using RWM, Sensitivity 
Analysis  or missing data methods does not change over year. The major measurements are 
proportion estimation, although the sample size is small, we do not believe that this may hinder 
the proportion estimation, confidence interval, and the conclusions of the review. 
Table 8 Meta-regression for three methods 
Mixed-effects Meta-regressions for three methods 
  name estimate Se z-score p-value ci_0.025 ci_0.975 




0.0049 0.0148 0.3310 0.7406 -0.0241 0.0340 
  name estimate Se z-score p-value ci_0.025 ci_0.975 
0 intercept 17.9639 49.1902 0.3651 0.7149 -78.4473 114.3751 
1 
Sensitivity 
Analysis -0.0088 0.0243 -0.3618 0.7174 -0.0566 0.0389 
  name estimate Se z-score p-value ci_0.025 ci_0.975 
0 intercept -23.1124 47.2377 0.4892 0.6246 115.6968 69.4719 




Multiple guidelines were published for how real-world data should be analyzed [14-17 26 32]. 
Our results suggest that, while the proportion of target studies using such methods have indeed 
risen over the past decade (EITHER rising from 10 to 20% OR meta-regression coefficient), 
even with the upper bound of the confidence interval, the actual rate is below 50% of studies. 
He estimate would be about 40%. 
We believe our estimates are reliable and our conclusion, indeed, so. First, we took a novel 
sampling approach to the scoping review. Since our goal was a proportion of articles, such a 
sample approach is justified. Now, we did find, near the end of the study, that the NLM search 
strategy for Electronic Health Data includes several journal limitations, we conducted the new 
search on August 18th, 2020, 935 more records were extracted than the original searching, and 
the study needs to be extended to include the articles we missed. However, those articles 
constitute about 1/3 of all articles in each epoch. Even if 100% of such articles used the RWM 
we are seeking, the . 
We biased our eligibility criteria to include studies that we would expect would use such 
methods. For instance, we did not exclude nine papers that used data from the National Trauma 
Data Bank (NTDB), [43-51] a large national database that attracts many researchers doing data 
analytic methodology related studies, the data were routinely collected and collated from trauma 
centers and trauma systems in the U.S.  [52-54]  However, the number of studies handled 
missing data is still low. A review in 2011 claims 10 % of articles used NTDB data handled 
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missing data [55], after almost 10 years, in our research 2 of those research handled missing data, 
and 4 mentioned missing data in limitation, only 1 used method suggested for Real-World Data. 
Third, we had 2 readers for judging inclusion/exclusion and determining the methods used within 
each included article. Our inter-rater reliabilities were 0.95 with agreement of  98%  and 0.97 
with agreement of  99%, both well above the kappa of .80 used as the practical threshold. [38]
One of the major challenges in the analysis of EHRs is the missing data problem [19 56]. Forty-
two included papers mentioned the missing data issue in the data cleaning or limitation session. 
However, only 15 of them handled the missing data. The estimated proportions of papers 
handled missing data problem are  0.17 (0,0.34), 0.21(0,0.43), and 0.02 (0.03,0.41) in 2017, 
2018, and 2019, respectively. If the missingness is Missing at Completely at Random (MCAR) 
or Missing at Random (MAR), the probability of missing record is independent of observed data 
or outcome measurements, dropping the whole record with missing elements would not 
influence the estimator. However, many papers included in this review drop the missing records 
directly without giving proof of MCAR  or MAR in a multivariate analysis. As a result, 
observations with missing values may lead to a biased result. 
Real-world Methods we defined contains a list of methods that could analyze the causal effects 
of observed data, and machine learning methods with proper causal inference.[32] Causal 
inference is constrained by the assumptions made in the design and analysis of the research and 
this is especially evident when dealing with data on clinical health. [20] The proportion 
estimation of papers used RWM in 2018 is 21%, an upper bound of 43%, studies used RWM is 
disappointingly low. EHRs are observational data, from the EHRs the population being studied is 
the same that is being treated. The evidence generated without proper study design and analysis 
cannot be interpreted as meaningful information. Thus it is limited when to inform decision-
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support. For example, only using linear regression on two variables extracted from EHR did not 
consider the counterfactual conditions; the result only can be construed as an association of two 
data variables. To better interpret RWD, investigators need the knowledge of informatics, 
epidemiology, and statistics is required. 
Sensitivity Analysis seeks to determine the appropriateness of a particular analytic model and 
consider the impact of the model's conclusions. Sensitivity analysis should be performed after 
the analytic model was built to validate the study's primary results[20 26]. In our results, the 
proportion estimations of studies conducted sensitivity analysis are 0.28(0.07, 0.48), 0.07(0, 
0.21), 0.22(0.03, 0.41) in 2017,2018 and 2019 , respectively. Although the guidelines proposed 
studies to do sensitivity analysis, only a small proportion of the study performed it. 
This review found that proper methods designed for RWD were not correctly used in the 
published studies. To reduce biases in analytics, to enhance the cooperation of different 
background investigators, a standard process needs to be proposed and followed for the RWD 
results report. 
Why might inadequate proper methods have been used and continue not to be used? At the first 
search, No facilitation/barrier study has been done, so we can only speculate on the following: 
• Analysts of EHR data come from backgrounds with little exposure to EHR data; 
• Informaticians who work with such data do not have the epidemiology and statistical 
background for their analysis; 
• The tool supplied for these analyses (e.g., HADES), are not easily found, accessible, 
interoperable with standard models, or easilty reused. 
Due to RWD's complexity, it is not accurate to use traditional data processing methods with 
large datasets. Despite the great value, EHRs may continue using inappropriate methods to 
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generate biased results against the original intention. In order to ensure internal and external 
validity in EHRs based research, researchers must determine whether the data are accurately 
extracted, adequately adjusted, correctly analyzed and cogently presented.[20] To understand 
and analyze the RWD in a proper method, it requires the investigators to collaborate in a 
multidisciplinary team that comprises clinicians, informaticians, epidemiologists, and 
biostatisticians (data scientists). 
The OHDSI (The Observational Health Data Sciences and Informatics)  developed tools to 
conduct real-world evidence generation.[30] From building Common Data Model (CDM), 
designing a study, defining cohort, building the analytics model, to generating the evidence, the 
RWD analytics is not a simple step. The set of tools are fantastic for conducting an observational 
study. However, for a small group of investigators, they may lack the ability to implement such a 
sophisticated toolset. There is a need to build an easily implemented research method decision-
support toolset or standard RWE generation pipeline for existing Real-World Databases. 
These suggestions have implications for education of statisticians and informaticians and for the 
need for statistical-analytic decision support tools, each of which is beyond the scope of this 
report. 
Limitations 
A limitation of this scoping review is it was not registered in any database. A search conducted 
in Cochrane Library and PROSPERO on August 18th, 2020, showed no similar systematic or 
scoping reviews were registered.  
We have implemented a comprehensive search strategy, literature sampling , and synthesis 
process in accordance with the guidance for conducting methodological reviews. [57]  The 
search strategy we used for the Electronic Health Record was retrieved form National Library of 
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Medicine MEDLINE / PubMed Search Strategy & Electronic Health Record Information 
Resources[33]. We found the strategy limited the literature to major journals in the EHRs 
research; the search strategy could lead to selection bias. For further investigation, more 
literature databases and adjusted search strategy need to be used. 
The number of included papers in each epoch is small,  and it should be increased for a more 
accurate analysis. However, we do not believe that this may hinder the proportion estimations 
and the conclusions of the review.  
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Appendix 1 Search Strategy Details ( on March 23rd, 2020) 





((health information exchange [tw] OR  hie [tw] OR rhio 
[tw] OR regional health information organization [tw] OR 
hl7 [tw] ORhealth level seven [tw] OR unified medical 
language system [majr] OR umls [tw] OR loinc [tw] OR 
rxnorm [tw] OR snomed [tw] OR icd9 cm [ti] OR icd 9 cm 
[ti] OR 
icd10 [ti] OR 
icd 10 [ti] OR 
metathesaurus [tw] OR 
patient card [tw] OR 
patient cards [tw] OR 
health card [tw] OR 
health cards [tw] OR 
electronic health data [tw] OR 
personal health data [tw] OR 
personal health record [tw] OR 
personal health records [tw] OR 
Health Records, Personal [Majr] OR 
Health Record, Personal [Majr] OR 
ehealth [tw] OR 
e-health [tw] OR 
medical informatics application [mh] OR 
medical informatics applications [mh] OR 
medical records system, computerized [mh] OR 
medical records systems, computerized [mh] OR 
computerized patient medical records [tw] OR 
automated medical record system [tw] OR 
automated medical record systems [tw] OR 
automated medical records system [tw] OR 
automated medical records systems [tw] OR 
computerized medical record [tw] OR 
computerized medical records [tw] OR 
computerized patient records [tw] OR 
computerized patient record [tw] OR 
computerized patient medical record [tw] OR 
electronic health record [tw] OR 
electronic health records [tw] OR 
Electronic Health Record [Majr] OR 
Electronic Health Records [Majr] OR 
electronic patient record [tw] OR 
electronic patient records [tw] OR 
 
MEDLINE / PubMed 
Search Strategy & 








electronic medical record [tw] OR 
electronic medical records [tw] OR 
electronic healthcare records [tw] OR 
electronic healthcare record [tw] OR 
electronic health care record [tw] OR 
electronic health care records [tw] OR 
archives [majr] OR 
ehr [tw] OR 
ehrs [tw] OR 
phr [tw] OR 
phrs [tw] OR 
emr [tw] OR 
emrs [tw] OR 
Health Information Systems [Majr] OR 
health information interoperability[mh] OR 
health information interoperability[tw]) AND 
(medical record [ti] OR 
medical records [mh] OR 
medical records [ti] OR 
patient record [ti] OR 
patient records [ti] OR 
patient health record [ti] OR 
patient health records [ti] OR 
patient identification system [mh] OR 
patient identification systems [mh] OR 
Patient Outcome Assessment[Majr] OR 
Patient Discharge Summaries[Majr] OR 
healthcare record [ti] OR 
healthcare records [ti] OR 
health care record [ti] OR 
health care records [ti] OR 
health record [ti] OR 
health records [ti] OR 
hospital information system [tw] OR 
hospital information systems [tw] OR 
umae [ti] OR 
attitude to computers [mh] OR 
medical informatics [ti] OR 
Information Technology[mh] OR 
Information Technology[tw])) 
OR 
((medical records systems, computerized [majr] OR 
medical records systems, computerized [mh] OR 
computerized patient medical record [tw] OR 
computerized patient medical records [tw] OR 
automated medical record system [tw] OR 
automated medical record systems [tw] OR 
automated medical records system [tw] OR 
automated medical records systems [tw] OR 
computerized medical record [tw] OR 
computerized medical records [tw] OR 
computerized patient records [tw] OR 
computerized patient record [tw] OR 
patient generated health data[mh] OR 
patient generated health data[tw] OR 
electronic health record [tw] OR 
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electronic health records [tw] OR 
electronic patient record [tw] OR 
electronic patient records [tw] OR 
electronic medical record [tw] OR 
electronic medical records [tw] OR 
electronic healthcare records [tw] OR 
electronic healthcare record [tw] OR 
electronic health care record [tw] OR 
electronic health care records [tw] OR 
unified medical language system [majr] OR 
unified medical language system [tw] OR 
umls [tw] OR 
loinc [tw] OR 
rxnorm [tw] OR 
snomed [tw] OR 
icd9 cm [ti] OR 
icd 9 cm [ti] OR 
icd10 [ti] OR 
icd 10 [ti] OR 
metathesaurus [tw] OR  
ehr [tw] OR 
ehrs [tw] OR 
phr [tw] OR 
phrs [tw] OR 
emr [tw] OR 
emrs [tw] OR 
meaningful use [tiab] OR 
meaningful use [tw] OR 
Meaningful Use [Majr]) 
AND 
(j ahima [ta] OR 
j am med inform assoc [ta] OR 
amia annu symp proc [ta] OR 
health data manag [ta] OR 
int j med inform [ta] OR 
yearb med inform [ta] OR 
telemed j e health [ta] OR 





"Study Characteristics"[Publication Type] AND “data”[All 
fileds] AND “analy*”[All Fields] NOT 




(Publication Types) with 
Scope Notes 








(sensitiv*[Title/Abstract] OR sensitivity and 
specificity[MeSH Terms] OR diagnose[Title/Abstract] OR 
diagnosed[Title/Abstract] OR diagnoses[Title/Abstract] 
OR diagnosing[Title/Abstract] OR 
diagnosis[Title/Abstract] OR diagnostic[Title/Abstract] OR 
diagnosis[MeSH:noexp] OR diagnostic * [MeSH:noexp] 
OR diagnosis,differential[MeSH:noexp] OR 
 








Appendix 2 PubMed searched result 
PubMed file -github 
Appendix 3 EndNote Library 
EndNote Library-github 
Appendix 4 Excel Database 
Excel-Database-github 
 
Table 9 Database Filed Definitions 
diagnosis[Subheading:noexp]) OR (risk*[Title/Abstract] 
OR risk*[MeSH:noexp] OR risk *[MeSH:noexp] OR 
cohort studies[MeSH Terms] OR group[Text Word] OR 
groups[Text Word] OR grouped [Text Word]) OR 
(incidence[MeSH:noexp] OR mortality[MeSH Terms] OR 
follow up studies[MeSH:noexp] OR prognos*[Text Word] 


















Source of truth for article entities; data 
taken from EndNote  
EndNote_ID From EndNote  
Article_Name From EndNote  
Abstract From EndNote  
Author_Institution From EndNote  
Year From EndNote  
Journal From EndNote  
PubMed_ID From EndNote  
L_Key_Words From EndNote  
Language From EndNote  
DOI From EndNote 
Article_Review 
 
One row per review; allows multiple 
reviews per article  
Recode_Review_ID Primary Key   
Reviewer_ID DD.Keyworks List  
EndNote_Index Foreign key for Article table  
Article_Name vlookup from Article table  
Review_Date Manually enter timestamp  
First_Author Manually enter   
Key_words Manually enter   
Research_Design(Primar
y Objective) 
Manually enter  
 
Review/Original Manually enter   
Study_Design_Type Select from DD.Keywords_List 
Study Type  
Database/Datasource Manually enter   
Analytic_tool Manually enter  
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Country/district  Manually enter   
X Manually enter   
Y Manually enter   
Z Manually enter   
Association_Type Manually enter   
Unit_of_Analysis Manually enter   
Check_List Manually enter   
Mentioned_Mission_Data Manually enter   
Handled_Missing_Data Manually enter   
Rate_of_Article Manually enter   
Include_in_Research Manually enter   
Exclusion Reason Select from Exclusion 
Criteria(DD.Keywords_List)  
Real-World_Method TRUE/FALSE searched from 
Methods_Used_ In_Literature table  
Sensitivity_Analysis TRUE/FALSE searched from 
Methods_Used_ In_Literature table  
Other_Notes 
 
Methods_Used_in_Literatures   One row per analytic method; enables 
multiple methods per review  
ML_ID Methods records ID   
Review_ID foreign key for Article_Review table  
EndNote_ID Foreign key for Article table  
Analytic_Method_ID foreign key for DD.Analytic_Method 
table  





Analytic_Method_ID Primary Key   
Analytic_Method_Name Manually enter   
Method_Category Enter based on Guidelines   
Domain Manually enter   
Definition Manually enter   
Definition_Source Manually enter   




Study_Design_Type A list generated from reading process  
Exclusion Reason A list defined before reading  
Reviewer A list defined before reading  





929 North Wolfe.St, Baltimore, Maryland 21205 
Tel:(+1) 443-635-8987  chenyu.li@jhmi.edu  linkedin.com/in/chenyu-li-80375196/ 
 
PROFILE 
Master of Science candidate concentrating in biomedical informatics, interested in Real world healthcare 
data analysis and decision support. Bachelor of Management specialized in Information Systems 
Management. 
 
EDUCATION BACKGROUND  
 08/2018-08/2020 Johns Hopkins University School of Medicine                                       GPA:3.8 
Master of Science in Health Sciences Informatics-Research 
Certificate in Health Finance and Management          
 08/2015-05/2016 Illinois Institute of Technology                                                    GPA:4.0 
Exchange Student - Information Technology Management                          
 09/2013-06/2018 Beijing University of Posts and Telecommunications (BUPT) GPA:3.4                
Bachelor of Management in Information Management and Information Systems       
 
ACADEMIC PROJECTS 
Johns Hopkins University                 Research Student Assistant                   Baltimore, MD 12/2018-   
 EHR Data quality analysis project- analyzed simulated weight data in a large database using R, 
summarized data quality pattern. 
 Cost-benefit analysis of a Telemedicine program in pediatric anesthesia preoperative-prepared 
program workflow, study design and data analysis plan.  
 Graduate thesis: Analytic Methods Used in Real-World Data Based Biomedical Research- A Sampled 
Methodological Scoping Review 
Mentor: Harold Lehmann   
Clinic Data Analysis with Python  Baltimore, MD 01/2020-03/2020 
 Used Python libraries Pandas, Matplotlib, Seaborn, Sklearn, PySpark to do data cleaning, 
visualization, analysis on Hopkins Precision Medicine Platform Asthma dataset;  
 Accomplished DataCamp certifications:  Python Programmer, Data Analysis with Python, Data 
Science for everyone with Python 
Real-time Disease Surveillance Systems for COPD  Baltimore, MD 01/2019-03/2019 
 Designed workflow and data-flow for a disease surveillance system; 
 Visualized Chronic Obstructive Pulmonary Disease (COPD) related data using Tableau; 
 Created a website for demonstrating the project.  
General Hospital of the People's Liberation Army (PLAGH) 
Medical Engineering Center, Research Assistant 
Beijing, China 12/2017-05/2018 
 Conducted literature review on 3 Common Data Model used in Biomedical research, summarized cons 
and pros of CDMs and presented the results to clinicians; 
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 Collaborated in a clinical research data sharing system deployment; 
 Extracted 10-year Emergency Department EHR data, Transformed into ODHSI OMOP CDM 5.0 
version used SQL and PostgreSQL database, and Loaded into a clinical research data sharing system; 
 Assisted Database performance monitoring and trouble shooting.  
 Advisor: Zhengbo Zhang      
 
INTERNSHIPS  
American College of Radiology, Application Development Intern                         Reston, VA 05/2019-08/2019 
 Developed Clinical Decision Support (CDS) tool through Agile methods; 
 Recognized workflow, dataflow from research papers and converted 6 research papers into radiology 
Clinical Decision Support tool modules using XML;  
 Analyzed XML schemas used in 2 different organizations, communicated with members in different 
groups, and created XML schema mapping rules.  
Project Manager : Sujith Nair                     Smita Kabra        
Accenture                                                                            Beijing, China 04/2017-12/2017 
 Management Consultant Intern - Healthcare Industry 
 Collaborated in industry benchmarking, competition analysis for a healthcare and biotechnology 
valley planning project; Analyzed biomedical industry chain, collected information for industry 
research report and prepared presentation deck; 
 IT Consultant Intern - Tobacco Industry, Foodservice Industry 
 Designed data analytic plan, visualized simulated sales using Tableau, and forecasted 3 months sales 
behavior used regression models for a tobacco production management project; Collaborated both 
technology and business tender documents for a digital sales planning platform. 
Qinghai University Affiliated Hospital, Information and Network Center  
Database Administration Intern 
Xining，China 07/2014-08/2014 
 Involved in daily hospital database maintenance;  
 Evaluated current Health Information Systems based on national criteria; 
 Assisted manager finished demanded analysis for an integrated platform upgrade. 
 
TEACHING ASSISTANT EXPERIENCE  
Health Sciences Informatics, Knowledge Engineering and 




 Taught by Dr. Harold Lehmann; 
 Organized course material, live talks, provide evaluation, and feedbacks for students 
 Assisted quizzes, assignments, and final projects grading. 
TIMES: Clinical Informatics Course for Medical Students Baltimore, 
MD 
02/2019-04/2019 
Taught by Dr. Ashwini Davison 
 Created learning objectives, materials, and testing examples for one session. 
 
SKILLS 
Language: English (Fluent speaking and writing), Mandarin (Native) 
Presentation, Visualization and Communication: PowerPoint, Axure, Tableau, E-Charts 
Data Management, Analytics: Oracle 12c, Access, MySQL, Excel, SQL, R, Python, Stata programming, 
Web Development: XML, HTML/CSS                          Software Development: Java, Python 
 
